CN118338904A - KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法 - Google Patents

KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法 Download PDF

Info

Publication number
CN118338904A
CN118338904A CN202280077624.6A CN202280077624A CN118338904A CN 118338904 A CN118338904 A CN 118338904A CN 202280077624 A CN202280077624 A CN 202280077624A CN 118338904 A CN118338904 A CN 118338904A
Authority
CN
China
Prior art keywords
inhibitor
kras
pharmaceutically acceptable
salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280077624.6A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔·哈林
詹姆斯·盖尔·克里斯滕森
薇琪·鲍卡特
彼得·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN118338904A publication Critical patent/CN118338904A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280077624.6A 2021-10-05 2022-10-04 KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法 Pending CN118338904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252384P 2021-10-05 2021-10-05
US63/252,384 2021-10-05
PCT/US2022/045619 WO2023059594A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment

Publications (1)

Publication Number Publication Date
CN118338904A true CN118338904A (zh) 2024-07-12

Family

ID=85803703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280077624.6A Pending CN118338904A (zh) 2021-10-05 2022-10-04 KRAS G12D抑制剂与PI3Ka抑制剂的组合及相关治疗方法

Country Status (10)

Country Link
US (1) US20240408098A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412716A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537139A (cg-RX-API-DMAC7.html)
KR (1) KR20240073112A (cg-RX-API-DMAC7.html)
CN (1) CN118338904A (cg-RX-API-DMAC7.html)
AU (1) AU2022359282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233566A1 (cg-RX-API-DMAC7.html)
IL (1) IL311834A (cg-RX-API-DMAC7.html)
MX (1) MX2024004213A (cg-RX-API-DMAC7.html)
WO (1) WO2023059594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250120981A1 (en) * 2023-10-12 2025-04-17 Mirati Therapeutics, Inc. Mrtx1133 pharmaceutical compositions
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
ES2738864T3 (es) 2013-03-12 2020-01-27 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS
AU2019355574A1 (en) 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof

Also Published As

Publication number Publication date
US20240408098A1 (en) 2024-12-12
EP4412716A1 (en) 2024-08-14
MX2024004213A (es) 2024-07-29
IL311834A (en) 2024-05-01
EP4412716A4 (en) 2025-08-13
AU2022359282A1 (en) 2024-04-11
WO2023059594A1 (en) 2023-04-13
KR20240073112A (ko) 2024-05-24
JP2024537139A (ja) 2024-10-10
CA3233566A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CN114761012B (zh) 组合疗法
US20240408098A1 (en) COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT
CN118401254A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
CN118382459A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
CN112955137B (zh) 组合疗法
CN118369119A (zh) KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法
US9744175B2 (en) Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
US10047078B2 (en) Aminothiazole compounds
US20250249003A1 (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
JP2024521788A (ja) 併用療法
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
CN118414173A (zh) 抗体-药物缀合物和parp1选择性抑制剂的组合
AU2014280354A1 (en) Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor
CN115038447A (zh) 用于治疗癌症的组合疗法
Abduelkarem et al. Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations
JP2013505939A (ja) 組合せ
CN118973580A (zh) 包含sos1抑制剂和mek抑制剂的组合疗法
HK40108895A (en) Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
HK40108579A (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
HK40109896A (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
JP5794873B2 (ja) 抗腫瘍剤
US20250042918A1 (en) Compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108895

Country of ref document: HK